Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
FDF
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
A Icatibant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Icatibant, including repackagers and relabelers. The FDA regulates Icatibant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Icatibant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Icatibant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Icatibant supplier is an individual or a company that provides Icatibant active pharmaceutical ingredient (API) or Icatibant finished formulations upon request. The Icatibant suppliers may include Icatibant API manufacturers, exporters, distributors and traders.
click here to find a list of Icatibant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Icatibant DMF (Drug Master File) is a document detailing the whole manufacturing process of Icatibant active pharmaceutical ingredient (API) in detail. Different forms of Icatibant DMFs exist exist since differing nations have different regulations, such as Icatibant USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Icatibant DMF submitted to regulatory agencies in the US is known as a USDMF. Icatibant USDMF includes data on Icatibant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Icatibant USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Icatibant suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Icatibant Drug Master File in Japan (Icatibant JDMF) empowers Icatibant API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Icatibant JDMF during the approval evaluation for pharmaceutical products. At the time of Icatibant JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Icatibant suppliers with JDMF on PharmaCompass.
A Icatibant written confirmation (Icatibant WC) is an official document issued by a regulatory agency to a Icatibant manufacturer, verifying that the manufacturing facility of a Icatibant active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Icatibant APIs or Icatibant finished pharmaceutical products to another nation, regulatory agencies frequently require a Icatibant WC (written confirmation) as part of the regulatory process.
click here to find a list of Icatibant suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Icatibant as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Icatibant API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Icatibant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Icatibant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Icatibant NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Icatibant suppliers with NDC on PharmaCompass.
Icatibant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Icatibant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Icatibant GMP manufacturer or Icatibant GMP API supplier for your needs.
A Icatibant CoA (Certificate of Analysis) is a formal document that attests to Icatibant's compliance with Icatibant specifications and serves as a tool for batch-level quality control.
Icatibant CoA mostly includes findings from lab analyses of a specific batch. For each Icatibant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Icatibant may be tested according to a variety of international standards, such as European Pharmacopoeia (Icatibant EP), Icatibant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Icatibant USP).
LOOKING FOR A SUPPLIER?
